Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.


All technologies
 are listed as non-confidential technical summaries.

Technologies were generated by academic institutions, entrepreneurs, and corporations.

Click the Tech Search button below to have Whiteboard 2 Boardroom® staff complete a personalized search for innovations to license from our research institution partners.

The most recent innovations from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available. 

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Treating Neurological Diseases, Autoimmune Disorders, and Muscular Disorders Using Rev-erb Modulators

Background
 

Rev-erbs are members of the nuclear receptor super-family of proteins. They regulate transcription for proteins involved in a number of physiological processes. As such, they represent an attractive drug target. Rev-erb agonists have potential in a number of therapeutic settings, including neurological diseases, autoimmune disorders, and muscular disorders. Currently, there are no modulators of rev-erb on the market.

 
 
 
Overview
 

Researchers at Saint Louis University have developed a new chemical series of rev-erb agonists. They have compiled in vitro and a limited amount of in vivo data to demonstrate the efficacy of these new compounds.

 
 
 
Benefits
 

The potential advantages of this technology over existing solutions include:

  • Increase pharmocokinetic properties
  • Increase potency of therapies
 
 
 
Applications
 

Potential applications of this technology include treating various diseases and disorders such as:

  • Neurological diseases, especially those related to anxiety disorders
  • Autoimmune disorders
  • Muscular disorders

Additional Details

Owner

St. Louis University

Intellectual Property Protection

Pending Patent



Interested? Request More Information